Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Completed · Phase 1

Conditions studied: Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

In brief

The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Key facts

Study ID

NCT01074632

Run by

Sumitomo Pharma America, Inc.

People needed

26

Starts

2009-05-01

Expected to finish

2009-09-01

Last updated by the study team

2011-09-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female 18 to 65 years of age
• BMI >= 19.5 and <= 37 kg/m2
• No clinically relevant abnormal laboratory values

You may not qualify if…

• History or presence of renal or hepatic insufficiency
• Participated in a clinical trial in the past 30 days
• Use of con meds that prolong the QT/QTc taken within 14 days prior to study drug administration

Where it is running

• California Clinical Trials — Glendale, California, United States
• Clinical Research Institute — Wichita, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.